A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
oleh: Eric J. Hsu, Xuezhi Cao, Benjamin Moon, Joonbeom Bae, Zhichen Sun, Zhida Liu, Yang-Xin Fu
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-05-01 |
Deskripsi
While recognized as the first effective immunotherapy for human cancer, IL-2 based immunotherapy still encounters several limitations in the clinic. Here, the authors design a cytokine receptor-masked IL-2 mutein prodrug that is selectively activated by matrix metalloproteinases in the tumor microenvironment, promoting anti-tumor immune response while minimizing systemic toxicity.